Data ClinicalTrials.gov & FDA CBER · fetched 2026-10-30 Full pipeline · Changelog · Corrections

Open Source Medicine Foundation

Upcoming vaccines

Built 31 October 2026

What is actually close. Regulatory filings that are open now, every registered trial readout due in the next 24 months, and the vaccines that were licensed in the last two years — each date labelled by how firm it is.

Jump to: applications under review · company-announced filings · readout calendar · recently licensed · by target disease · how to read this

Applications a regulator says are under review

These are taken from the lists the regulators publish themselves, so the fact that an application is open is the regulator's statement, not a company's. An application under review is not an approval and carries no promised decision date. Each list is a snapshot: it says what was pending on the day it was published, named in the heading, and a decision may have been taken since.

EU — 3 applications Applications for new human medicines under evaluation by the CHMP, 2026-10; list as of 5 October 2026

Product, as the regulator names it Reference Under review since
Influenza mRNA vaccine Immunisation for the prevention of influenza disease in adults
Evaluation re-started after the regulator's questions on 17 August 2026 Tracked here as mRNA-1010 — Only mRNA influenza vaccine on the EU list; its indication is influenza alone, not the influenza/COVID-19 combination tracked as mrna-1083. The pipeline row records a Moderna EU filing for a seasonal-influenza mRNA vaccine in January 2026 and the EMA evaluation started 22 January 2026. Link is for navigation; the EMA list does not name a developer or a candidate code.
EMEA/H/C/006204 22 January 2026 regulator-confirmed
Japanese Encephalitis Chimeric Vaccine Substipharm Immunisation against Japanese encephalitis in adults, adolescents, children and infants aged 9 months and older No candidate for this product in the pipeline dataset. EMEA/H/C/006764 21 May 2026 regulator-confirmed
Lyme borreliosis vaccine (6-valent, recombinant, adsorbed) Immunisation for the prevention of Lyme disease in individuals 5 years of age and older Tracked here as VLA15 — Two Lyme candidates are tracked: VLA15 (protein subunit, OspA, phase 3) and mRNA-1982 (mRNA, phase 2). The EU row says recombinant and adsorbed, which is the protein-subunit product, not the mRNA one. Link is for navigation; the EMA list does not name a developer or a candidate code. EMEA/H/C/006771 13 August 2026 regulator-confirmed

Initial EU marketing-authorisation applications whose CHMP evaluation has started. Extensions of an existing authorisation are published separately and are not in this file. Source: Applications for new human medicines under evaluation by the CHMP, 2026-10.

One source could not be read for this build. Health Canada's list of new drug submissions under review did not respond to this build, so any application pending there is missing from the table above. That is a gap in what could be fetched, not a statement that nothing is pending.

The United States is missing from this section by necessity. The FDA publishes no list of pending licence applications, so there is no equivalent source to read; a US filing can only ever reach this page as a company statement, below. Japan, the UK, China and India publish no list this build can read either.

Filings a company has announced

Hand-curated from company disclosures, and kept apart from the regulator lists above on purpose: a company saying it has filed is weaker evidence than a regulator saying it is reviewing. The chip after each date says which it is. Company-announced timelines slip often, and where a date here is old the row says so rather than implying the filing is still open. A candidate's development stage may also lag what a regulator's list shows — the stage comes from trial records, not from the filing.

Ixchiq (VLA1553 / Chikungunya live-attenuated vaccine)

Valneva · Chikungunya · Live attenuated

Post-marketing safety surveillance; adolescent trial data readout

mRNA-1010

Moderna · Seasonal influenza · mRNA

Regulatory decision(s) pending across filed jurisdictions (company projection)

mRNA-1083 (Moderna Combined Influenza + COVID-19 mRNA Vaccine)

Moderna · Seasonal influenza + COVID-19 (combination) · mRNA

FDA target PDUFA action date and ACIP review for 2025-2026 respiratory season

Readout calendar: the next 24 months

Primary completion dates for registered trials of candidates that are still active, straight from ClinicalTrials.gov. A readout is not an approval — it is the date the sponsor expects to finish collecting the primary outcome, and sponsors revise these dates routinely. Trials marked terminated, withdrawn or suspended are left out, and a date that names no month (such as a bare “2025–2026”) is left out rather than guessed.

Q4 2026 32 readouts

ExpectedCandidate TargetPhase Trial
1 October 2026 AZD6489 AstraZeneca RSV Phase 1/2 NCT07717840
October 2026 BNT163 BioNTech SE Genital Herpes Simplex Type 2 Phase 1 NCT05432583
October 2026 Haemophilus Influenzae Type b Conjugate Vaccine CanSino Biologics Inc. Influenza Phase 1 NCT06621654
5 October 2026 mRNA-1189 ModernaTX, Inc. EBV Phase 1/2 NCT05164094
13 October 2026 mRNA-1195.1 ModernaTX, Inc. EBV Phase 1 NCT05831111
October 2026 VLP-Polio medium dose CanSino Biologics Inc. Polio Phase 1/2 NCT06577298
18 November 2026 COVID-19 Therapeutic Biologic Mix - NOVAVAX COVID-19 VACCINE plus BCG Vaccine Mix for percutaneous use Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair COVID-19 EARLY Phase 1 NCT03305341
23 November 2026 dTpa GlaxoSmithKline Diphtheria / Tetanus / Pertussis Phase 3 NCT07596199
November 2026 experimental vaccine Sinovac Biotech Co., Ltd Meningococcal disease Phase 3 NCT07505888
30 November 2026 Jynneos Bavarian Nordic Mpox Phase 2 NCT07199569
23 November 2026 Marketed varicella vaccine GlaxoSmithKline Varicella / Zoster Phase 3 NCT06693895
26 November 2026 Omicron Subvariant-Based SARS-CoV-2 Recombinant Spike Vaccine Adjuvanted With Matrix-M Sanofi COVID-19 Phase 4 NCT07861542
24 November 2026 PCV24 vaccine (dose H) CanSino Biologics Inc. Pneumococcal disease Phase 1/2 NCT07600983
19 November 2026 Pn-MAPS30plus GlaxoSmithKline Pneumococcal disease Phase 1 NCT07428759
November 2026 Recombinant Poliomyelitis Vaccine (rPV) Serum Institute of India Pvt. Ltd. Polio Phase 1 NCT07688369
30 November 2026 V540D (HPV vaccine) Merck Sharp & Dohme LLC HPV Phase 1 NCT06688058
28 November 2026 Yellow fever vaccine (live) Sanofi Yellow fever Phase 3 NCT07103148
31 December 2026 Cervavac as two dose regimen Serum Institute of India Pvt. Ltd. HPV Phase 3 NCT06281119
December 2026 Egg-based Trivalent Split Influenza Virus Vaccine (eTIV) Sinovac Biotech Co., Ltd Influenza Phase 1 NCT07889193
31 December 2026 HPV vaccine University of Washington HPV Phase 4 NCT05291871
31 December 2026 HPV vaccine University of Washington HPV Phase 4 NCT04235257
31 December 2026 Influenza vaccination Wroclaw Medical University Influenza Phase 4 NCT07617376
3 December 2026 Licensed Seasonal Influenza Vaccine GlaxoSmithKline COVID-19 Phase 1 NCT07464314
14 December 2026 Marketed varicella vaccine GlaxoSmithKline Varicella / Zoster Phase 3 NCT06806137
25 December 2026 Marketed varicella vaccine_Lot 1 GlaxoSmithKline Varicella / Zoster Phase 3 NCT06740630
11 December 2026 mRNA-1273 ModernaTX, Inc. COVID-19 Phase 4 NCT07863635
31 December 2026 mRNA-1273 Variant-containing Formulation ModernaTX, Inc. COVID-19 Phase 4 NCT06585241
December 2026 Nonavalent HPV vaccine (9vHPV/Gardasil-9™). Miquel Angel Pavon Ribas HPV Phase 4 NCT05334706
1 December 2026 Pandemic flu H5 HA mRNA SD2 vaccine Sanofi Influenza Phase 1/2 NCT06907511
30 December 2026 Pneumococcal Vaccine University of Sao Paulo General Hospital Autoimmune Rheumatologic Disease Phase 4 NCT07252791
30 December 2026 Sinovac Rabies Vaccine (Serum-free Vero Cell), Freeze-dried Sinovac Biotech Co., Ltd Rabies Phase 3 NCT07055295
December 2026 Trumenba Emory University Meningococcal disease Phase 4 NCT07197762

Q1 2027 22 readouts

ExpectedCandidate TargetPhase Trial
15 January 2027 9vHPV vaccine Merck Sharp & Dohme LLC Papillomavirus Infections Phase 3 NCT04199689
12 January 2027 Adjuvanted RSVPreF3 vaccine GlaxoSmithKline RSV Phase 2 NCT07092865
January 2027 experimental vaccine Sinovac Biotech Co., Ltd Meningococcal disease Phase 3 NCT07505836
18 January 2027 Licensed RSV Vaccine Sanofi Pasteur, a Sanofi Company RSV Phase 1/2 NCT06686654
January 2027 Moderna RSV vaccine Emory University RSV Phase 4 NCT07185399
28 January 2027 mRNA-1018-H5 ModernaTX, Inc. Influenza Phase 3 NCT07496450
7 January 2027 PCV21 Sanofi Pneumococcal disease Phase 3 NCT07247188
15 January 2027 Recombinant Human Papillomavirus Bivalent Vaccine National Cancer Institute (NCI) HPV Phase 4 NCT05237947
29 January 2027 rF1V-1018 Dynavax Technologies Corporation Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersinia Pestis Phase 2 NCT07207408
January 2027 RSV Vaccine Canadian Immunization Research Network RSV Phase 4 NCT07097012
18 January 2027 RSVpreF Pfizer RSV Phase 3 NCT05035212
25 January 2027 RSVpreF Pfizer RSV Phase 3 NCT07653100
28 February 2027 9-valent HPV vaccine (Cecolin 9) Xiamen Innovax Biotech Co., Ltd HPV Phase 4 NCT07668271
February 2027 Anflu® Sinovac Biotech Co., Ltd Influenza Phase 4 NCT07832201
15 February 2027 mRNA-1403 ModernaTX, Inc. Norovirus Phase 3 NCT06592794
February 2027 MVA-BN-WEV Bavarian Nordic Encephalitis Phase 2 NCT06899802
15 February 2027 PCV13i CanSino Biologics Inc. Pneumococcal disease Phase 3 NCT07017777
22 February 2027 Pn-MAPS30plus GlaxoSmithKline Pneumococcal disease Phase 1 NCT07406334
6 March 2027 mRNA-1647 ModernaTX, Inc. CMV Phase 2 NCT05683457
March 2027 Sinovac PCV13 lot 1 Sinovac Life Sciences Co., Ltd. Pneumococcal disease Phase 3 NCT07832500
March 2027 VAX-31 (31-valent pneumococcal conjugate vaccine) Vaxcyte, Inc. Pneumococcal disease Phase 3 NCT07425392
March 2027 VAX-31 (31-valent pneumococcal conjugate vaccine) Vaxcyte, Inc. Pneumococcal disease Phase 3 NCT07365826

Q2 2027 22 readouts

ExpectedCandidate TargetPhase Trial
21 April 2027 BNT162b2 BioNTech SE COVID-19 Phase 3 NCT07798648
April 2027 experimental vaccine Sinovac Biotech Co., Ltd Meningococcal disease Phase 3 NCT07505823
April 2027 experimental vaccine Sinovac Biotech Co., Ltd Meningococcal disease Phase 3 NCT07505810
4 April 2027 H5 Flu IMP 2 Sanofi Influenza Phase 1 NCT07516418
30 April 2027 H5N1 vaccine (Arepanrix, GSK) University Health Network, Toronto Influenza Phase 3 NCT07240558
23 April 2027 RTS,S/AS01E vaccine GlaxoSmithKline Malaria Phase 2 NCT07036159
1 April 2027 Seasonal influenza vaccine University of Pennsylvania Influenza Phase 4 NCT05108818
14 April 2027 TDV Takeda Dengue Phase 3 NCT06579755
17 May 2027 MenACYW conjugate vaccine Sanofi Pasteur, a Sanofi Company Meningococcal disease Phase 1/2 NCT06647407
15 May 2027 mRNA-1189 ModernaTX, Inc. EBV Phase 1 NCT07478952
1 May 2027 PG4 Pfizer Pneumococcal disease Phase 2 NCT06524414
16 May 2027 RSVpreF Pfizer RSV Phase 3 NCT07819097
17 May 2027 Sanofi PCV21 (21-valent pneumococcal conjugate vaccine) Sanofi Pneumococcal disease Phase 3 NCT06736041
1 May 2027 Vaxigrip Tetra Sanofi Pasteur Europe Aarhus University Hospital Influenza Phase 4 NCT05585983
10 June 2027 20vPnC Pfizer Pneumococcal disease Phase 1 NCT07023081
June 2027 BNT166a BioNTech SE Mpox Phase 2 NCT07379580
29 June 2027 Low dose Strep A Alum GlaxoSmithKline Streptococcal Infections Phase 1 NCT07085702
16 June 2027 mRNA-1273 ModernaTX, Inc. COVID-19 Phase 4 NCT07266558
22 June 2027 Pfizer mRNA influenza vaccine candidates (#1-#6, unnamed) Pfizer Influenza Phase 2 NCT07431853
7 June 2027 PG4 Multivalent Vaccine Pfizer Pneumococcal disease Phase 3 NCT07794748
7 June 2027 Sanofi PCV21 (21-valent pneumococcal conjugate vaccine) Sanofi Pneumococcal disease Phase 3 NCT07348692
June 2027 Z-1018 Dynavax Technologies Corporation Varicella / Zoster Phase 1/2 NCT06569823

Q3 2027 11 readouts

ExpectedCandidate TargetPhase Trial
9 July 2027 Comparator 1 GlaxoSmithKline Influenza Phase 3 NCT07851246
20 July 2027 mRNA-1365 (Profile 2) ModernaTX, Inc. RSV Phase 1 NCT07764237
30 July 2027 Recombinant Zoster Vaccine (RZV) University of Sao Paulo General Hospital Varicella / Zoster Phase 4 NCT07280741
July 2027 Sinovac PCV13 (13-valent pneumococcal conjugate vaccine) Sinovac Life Sciences Co., Ltd. Pneumococcal disease Phase 3 NCT07593924
6 July 2027 V118E (V118 formulation E, pneumococcal vaccine) Merck Sharp & Dohme LLC Pneumococcal disease Phase 1 NCT07168915
August 2027 9-valent HPV vaccine, 3 doses standard timing The University of Texas Medical Branch, Galveston HPV Phase 4 NCT05672927
20 August 2027 BNT162b2 Vaccine BioNTech SE COVID-19 Phase 4 NCT07730450
23 August 2027 HZ/su vaccine GlaxoSmithKline Varicella / Zoster Phase 3 NCT05371080
25 August 2027 Sanofi PCV21 (21-valent pneumococcal conjugate vaccine) Sanofi Pneumococcal disease Phase 3 NCT06975878
15 September 2027 Hepatitis A vaccine (inactivated, adsorbed) Sinovac Biotech Co., Ltd Hepatitis A Phase 3 NCT07793227
10 September 2027 Sanofi PCV21 (21-valent pneumococcal conjugate vaccine) Sanofi Pneumococcal disease Phase 3 NCT06824181

Q4 2027 10 readouts

ExpectedCandidate TargetPhase Trial
October 2027 HEXASIIL Serum Institute of India Pvt. Ltd. Influenza Phase 1/2 NCT07855172
21 October 2027 PG4 in Buffer 1 with low dose PA-002 Pfizer Pneumococcal disease Phase 1 NCT07086677
22 October 2027 Sanofi PCV21 (21-valent pneumococcal conjugate vaccine) Sanofi Pneumococcal disease Phase 3 NCT06824194
November 2027 Pfs230D1-CRM197 + R21/Matrix-M1 (malaria) Serum Institute of India Pvt. Ltd. Malaria Phase 2 NCT07147400
14 November 2027 Typhoid Vi conjugate vaccine GlaxoSmithKline Salmonella Infections Phase 1 NCT07663032
December 2027 0.5 mL of the low dose VAX-31 Vaxcyte, Inc. Pneumococcal disease Phase 2 NCT06720038
2 December 2027 PG4 Pfizer Pneumococcal disease Phase 3 NCT07660198
30 December 2027 Pneumococcal Vaccine University of Sao Paulo General Hospital Autoimmune Rheumatologic Disease Phase 4 NCT07242092
18 December 2027 V503 Merck Sharp & Dohme LLC HPV Phase 3 NCT07785843
December 2027 VAX-A1 (Group A Streptococcus vaccine) Vaxcyte, Inc. Group A Streptococcal Infection Phase 1 NCT07616934

Q1 2028 10 readouts

ExpectedCandidate TargetPhase Trial
3 January 2028 Chlamydia mRNA Vaccine Sanofi Chlamydia Trachomatis Immunization Phase 1/2 NCT06891417
February 2028 10vHPV Serum Institute of India Pvt. Ltd. HPV Phase 1/2 NCT07888686
February 2028 BNT168 BioNTech SE HIV Phase 1 NCT07698600
February 2028 CHIKV VLP vaccine (PXVX0317, Vimkunya) Bavarian Nordic Chikungunya Phase 3 NCT06007183
22 February 2028 Flu H5 egg pandemic low dose vaccine, with adjuvant Sanofi Influenza Phase 1/2 NCT07779408
28 February 2028 MMRVNS (GSK investigational MMRV vaccine) GlaxoSmithKline Measles / Mumps / Rubella Phase 3 NCT07406360
24 February 2028 RSVpreF Pfizer RSV Phase 3 NCT06866405
2 February 2028 RSVpreF Vaccine Pfizer RSV Phase 3 NCT07768345
17 March 2028 Healive (hepatitis A vacine(human diploid cell), inactivated) Sinovac Biotech Co., Ltd Hepatitis A Phase 4 NCT06058416
13 March 2028 MenQuadfi® (Meningococcal Polysaccharide [Serogroups A, C, W, and Y] Tetanus Toxoid Conjugate Vaccine) (Sanofi Pasteur I Sanofi Meningococcal disease Phase 3 NCT07710872

Q2 2028 5 readouts

ExpectedCandidate TargetPhase Trial
27 April 2028 iNTS-TCV (GSK/GVGH invasive nontyphoidal Salmonella + typhoid conjugate vaccine) GlaxoSmithKline Invasive nontyphoidal Salmonella / Typhoid Phase 2 NCT07286370
5 May 2028 PREVNAR 20™ Merck Sharp & Dohme LLC Healthy Phase 1 NCT07712575
3 May 2028 RSV+HMPV vaccine Sanofi RSV Phase 1/2 NCT07734649
31 May 2028 V540B (HPV vaccine) Merck Sharp & Dohme LLC HPV Phase 1 NCT06623409
27 June 2028 MMRV vaccine GlaxoSmithKline Measles / Mumps / Rubella Phase 3 NCT07742644

Q3 2028 3 readouts

ExpectedCandidate TargetPhase Trial
17 July 2028 V350 (V350A / V350B, EBV vaccine) Merck Sharp & Dohme LLC Epstein-Barr virus Phase 1 NCT06655324
August 2028 CLDN6 CAR-T BioNTech Cell & Gene Therapies GmbH Solid Tumor Phase 1 NCT04503278
September 2028 Gardasil-9 Emory University HPV Phase 4 NCT06799494

Q4 2028 4 readouts

ExpectedCandidate TargetPhase Trial
31 October 2028 altSonflex1-2-3 (GSK Shigella vaccine) GlaxoSmithKline Shigellosis Phase 2 NCT07320716
1 October 2028 Early intervention Centre Hospitalier Universitaire de Saint Etienne Pneumococcal disease Phase 4 NCT06822907
18 October 2028 Pn-MAPS30plus GlaxoSmithKline Pneumococcal disease Phase 1 NCT07406347
24 October 2028 V118C (Stage 1) Merck Sharp & Dohme LLC Pneumococcal disease Phase 1 NCT07300267

Licensed in the last 24 months

Only licences and authorisations whose date is marked regulator-confirmed in the pipeline file. A vaccine licensed outside the jurisdictions tracked here (US, EU, Canada, Australia, UK) will not appear.

VaccineTarget LicensedOn this site
MFLUSIVA Influenza Vaccine, mRNA ModernaTX, Inc. Influenza US 5 August 2026 guide
NUVAXOVID Novavax Inc. COVID-19 US 16 May 2025 guide
MNEXSPIKE Moderna TX, Inc. COVID-19 US 30 May 2025 guide
VIMKUNYA Bavarian Nordic A/S Bavarian Nordic, Inc. Chikungunya US 14 February 2025 —
PENMENVY See FDA listing Meningococcal disease US 14 February 2025 guide

By target disease

Active candidates per target, with the nearest expected readout. “Phase 3” counts candidates whose most advanced active trial is phase 3. Where this site has a guide to the vaccines already licensed for a disease, it is linked; where it says none yet, that means no guide here, not that no vaccine exists.

Target diseaseActive Phase 3Next readout Licensed vaccines
HPV 18 14 November 2026 guide
Pneumococcal disease 21 11 November 2026 guide
Influenza 24 9 October 2026 guide
Varicella / Zoster 13 9 November 2026 guide
RSV 24 8 October 2026 guide
COVID-19 16 7 November 2026 guide
Meningococcal disease 14 7 November 2026 guide
Measles / Mumps / Rubella 7 5 February 2028 guide
Dengue 4 3 April 2027 none yet
Chikungunya 6 2 February 2028 none yet
Seasonal influenza + COVID-19 (combination) 3 2 — guide
Yellow fever 3 2 November 2026 guide
Diphtheria / Tetanus / Pertussis 2 2 November 2026 guide
Hepatitis A 2 2 September 2027 guide
Rabies 2 2 December 2026 guide
Hepatitis B 3 1 — guide
Polio 3 1 October 2026 guide
Clostridoides Difficile Associated Disease 2 1 — none yet
Lyme disease 2 1 — none yet
Rotavirus 2 1 — guide
Autoimmune Rheumatologic Disease 1 1 December 2026 none yet
CMV 1 1 March 2027 none yet
Hand, Foot, and Mouth Disease(HFMD) 1 1 — none yet
Invasive pneumococcal disease (31-valent conjugate) 1 1 — guide
Norovirus 1 1 February 2027 none yet
Papillomavirus Infections 1 1 January 2027 guide
EBV 2 — October 2026 none yet
Malaria 2 — April 2027 none yet
Mpox 2 — November 2026 none yet
Tuberculosis 2 — — none yet
Acne 1 — — none yet
Anthrax (post-exposure) 1 — — none yet
Chlamydia Trachomatis Immunization 1 — January 2028 none yet
Diphtheria / Tetanus / Pertussis / Hib / Meningococcal 1 — — guide
Diphtheria / Tetanus / Pertussis / Polio / Hib / HepB 1 — — guide
Ebola 1 — — none yet
Encephalitis 1 — February 2027 none yet
Epstein-Barr virus 1 — July 2028 none yet
Genital Herpes Simplex Type 2 1 — October 2026 none yet
Group A Streptococcal Infection 1 — December 2027 none yet
HIV 1 — February 2028 none yet
Healthy 1 — May 2028 none yet
Immunoglobulin A Nephropathy (IgAN) 1 — — none yet
Invasive nontyphoidal Salmonella / Typhoid 1 — April 2028 guide
Melanoma 1 — — none yet
Mpox / Smallpox 1 — — none yet
Multiple Sclerosis 1 — — none yet
Non-Small Cell Lung Cancer 1 — — none yet
Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersinia Pestis 1 — January 2027 none yet
RSV / hMPV / PIV3 1 — — guide
Salmonella Infections 1 — November 2027 none yet
Seasonal influenza 1 — — guide
Shigellosis 1 — October 2028 none yet
Solid Tumor 1 — August 2028 none yet
Stage 4 NSCLC 1 — — none yet
Streptococcal Infections 1 — June 2027 none yet

How to read this page

The full filterable table of all 335 candidate records, including discontinued programmes, is at the vaccine pipeline dashboard; each candidate also has its own page. Viruses and what exists against them are in the Virus Navigator, and the gap matrix lists targets with no vaccine and no antiviral at /virus-navigator/gaps.html.

Cite this page. Upcoming vaccines: filings open and trial readouts ahead. Vaccine Data Navigator, Open Source Medicine Foundation. Built 31 October 2026 from ClinicalTrials.gov API v2 (fetched 2026-10-30) and FDA CBER listings. https://vaccinedatanavigator.org/upcoming-vaccines.html

Report an error